p21-Activated Kinases Present a New Drug Target for Hypertrophic Cardiomyopathy

Yu He; Ming Lei

doi:10.53941/ijddp.2023.100006

Abstract

Hypertrophic cardiomyopathy (HCM), primarily involving mutations in sarcomeric proteins, is the most common form of inherited heart disease and a leading cause of sudden death in young adults and athletes. HCM patients present with cardiac hypertrophy, fibrosis, and diastolic dysfunction often in a progressive manner. Despite significant progress made in understanding the molecular genetic basis of HCM, there remains a lack of effective and specific treatment for preventing disease progression in HCM. This article first provides an overview of recent progress in understanding the pathogenic basis of disease progression in HCM, in particular dysfunctional calcium handling, mitochondrial impairment, and endoplasmic reticulum stress. This article then analyses the evidence for critical roles of the multifunctional enzymes P21-activated kinase-1 and 2 (Pak1/2) in the heart and our opinion on their therapeutic value as a promising druggable target in pathological hypertrophy and associated ventricular arrhythmias.

References

1.
Maron B.J.; Desai M.Y.; NishimuraR.A.; et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol., 2022, 79(4): 372-389.
2.
Walsh R.; ThomsonK.L.; WareJ.S.; et al. Reassessment of mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet. Med., 2017, 19(2): 192-203.
3.
O'Mahony C.; Akhtar M.M.; Anastasiou Z.; et al. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2019, 105(8): 623-631.
4.
Prondzynski M.; Mearini G.; Carrier L. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. Pflügers Archi., 2019, 471(5): 807-815.
5.
Harper A.R.; Goel A.; Grace C.; et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet., 2021, 53(2): 135-142.
6.
Watkins H. Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. Circulation, 2021, 143(25): 2415-2417.
7.
Schober T.; Huke S.; Venkataraman R.; et al. Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia. Circ. Res., 2012, 111(2): 170-179.
8.
Robinson P.; Liu X.; Sparrow A.; et al. Hypertrophic cardiomyopathy mutations increase myofilament Ca2+ buffering, alter intracellular Ca2+ handling, and stimulate Ca2+-dependent signaling. J. Biol. Chem., 2018, 293(27): 10487-10499.
9.
Lucas D.T.; Aryal P.; Szweda L.I.; et al. Alterations in mitochondrial function in a mouse model of hypertrophic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 2003, 284(2): H575-H583.
10.
Ranjbarvaziri S.; Kooiker B.; Ellenberger M.; et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation, 2021, 144(21): 1714-1731.
11.
Ashrafian H.; Redwood C.; Blair E.; et al. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet., 2003, 19(5): 263-268.
12.
Sweeney H.L.; Feng H.S.; Yang Z.; et al. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Proc. Natl. Acad. Sci., 1998, 95(24): 14406-14410.
13.
Frey N.; Brixius K.; Schwinger R.H.G.; et al. Alterations of tension-dependent ATP utilization in a transgenic rat model of hypertrophic cardiomyopathy. J. Biol. Chem., 2006, 281(40): 29575-29582.
14.
Bousette N.; Chugh S.; Fong V.; et al. Constitutively active calcineurin induces cardiac endoplasmic reticulum stress and protects against apoptosis that is mediated by α-crystallin-B. Proc. Natl. Acad. Sci., 2010, 107(43): 18481-18486.
15.
Langa P.; Wolska B.M.; Solaro R.J. The hippo signaling pathway as a drug target in familial dilated cardiomyopathy. Inter. J. Drug Discov. Pharmacol., 2022, 1(1): 4.
16.
Ashrafian H.; McKenna M.J.; WatkinsH.; et al. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ. Res., 2011, 109(1): 86-96.
17.
Wu H.D.; Yang H.X.; RheeJ.W.; et al. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. Eur. Heart J., 2019, 40(45): 3685-3695.
18.
Peña J.R.; Szkudlarek A.C.; Warren C.M.; et al. Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol., 2010, 49(6): 993-1002.
19.
Belus A.; Piroddi N.; Scellini B.; et al. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J. Physiol., 2008, 586(15): 3639-3644.
20.
Christiansen M.; Hagen C.M.; Hedley P.L. Mitochondrial haplogroups are associated with hypertrophic cardiomyopathy in the Indian population. Mitochondrion, 2015, 20: 105-106.
21.
Zhang Y.M.; Wang J.; Zhou Y.F.; et al. Generation of two induced pluripotent stem cell lines (XACHi0010-A, XACHi0011-A) from a Chinese family with combined oxidative phosphorylation deficiency carrying homozygous and heterozygous C1QBP-L275F mutation. Stem Cell Res., 2020, 47: 101912.
22.
Chung H.; Kim Y.; Cho S.M.; et al. Differential contributions of sarcomere and mitochondria-related multigene variants to the endophenotype of hypertrophic cardiomyopathy. Mitochondrion, 2020, 53: 48-56.
23.
Schwarz D.S.; Blower M.D. The endoplasmic reticulum: structure, function and response to cellular signaling. Cell. Mol. Life Sci., 2016, 73(1): 79-94.
24.
Wang S.Y.; Binder P.; Fang Q.R.; et al. Endoplasmic reticulum stress in the heart: insights into mechanisms and drug targets. Br. J. Pharmacol., 2018, 175(8): 1293-1304.
25.
Lin J.H.; Walter P.; Yen T.S.B. Endoplasmic reticulum stress in disease pathogenesis. Annu. Rev. Pathol.: Mech. Dis., 2008, 3: 399-425.
26.
Kaski J.P.; Tomé Esteban M.T.T.; Lowe M.; et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart, 2007, 93(3): 372-374.
27.
Sherrid M.V. Drug therapy for hypertrophic cardiomypathy: physiology and practice. Curr. Cardiol. Rev., 2016, 12(1): 52-65.
28.
Abozguia K.; Elliott P.; McKenna W.; et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation, 2010, 122(16): 1562-1569.
29.
Axelsson A.; Iversen K.; VejlstrupN.; et al. Efficacy and safety of the angiotensin Ⅱ receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol., 2015, 3(2): 123-131.
30.
Heitner S.B.; JacobyD.; LesterS.J.; et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann. Intern. Med., 2019, 170(11): 741-748.
31.
Keam S.J. Mavacamten: first approval. Drugs, 2022, 82(10): 1127-1135.
32.
Xu H.L.; Wang D.W.; Ramponi C.; et al. The P21-activated kinase 1 and 2 as potential therapeutic targets for the management of cardiovascular disease. Inter. J. Drug Discov. Pharmacol., 2022, 1(1): 5.
33.
Ke Y.; Lei M.; Collins T.P.; et al. Regulation of L-type calcium channel and delayed rectifier potassium channel activity by p21-activated kinase-1 in guinea pig sinoatrial node pacemaker cells. Circ. Res., 2007, 100(9): 1317-1327.
34.
Egom E.E.A.; Ke Y.; Musa H.; et al. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J. Mol. Cell. Cardiol., 2010, 48(2): 406-414.
35.
Egom E.E.A.; Mohamed T.M.A.; Mamas M.A.; et al. Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am. J. Physiol. Heart Circ. Physiol., 2011, 301(4): H1487-H1495.
36.
Liu W.; Zi M.; Naumann R.; et al. Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation, 2011, 124(24): 2702-2715.
37.
Liu W.; Zi M.; Tsui H.; et al. A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ.: Heart Failure, 2013, 6(4): 833-844.
38.
DeSantiago J.; Bare D.; Ke Y.B.; et al. P21-Activated kinase (Pak1) is a negative regulator of ROS generation in ventricular myocytes. Biophys. J., 2013, 104(2 Supplement 1): 614A.
39.
DeSantiago J.; Bare D.J.; XiaoL.; et al. p21-Activated kinase1 (Pak1) is a negative regulator of NADPH-oxidase 2 in ventricular myocytes. J. Mol. Cell. Cardiol., 2014, 67: 77-85.
40.
Wang R.; Wang Y.W.; Lin W.K.; et al. Inhibition of angiotensin Ⅱ-induced cardiac hypertrophy and associated ventricular arrhythmias by a p21 activated kinase 1 bioactive peptide. PLoS One, 2014, 9(7): e101974.
41.
Wang Y.W.; TsuiH.; KeY.B.; et al. Pak1 is required to maintain ventricular Ca2+ homeostasis and electrophysiological stability through SERCA2a regulation in mice. Circ.: Arrhythmia Electrophysiol., 2013, 6(4): 833-844.
42.
Tsui H.; Zi M.; Wang S.Y.; et al. Smad3 couples Pak1 with the antihypertrophic pathway through the E3 ubiquitin ligase, Fbxo32. Hypertension, 2015, 66(6): 1176-1183.
43.
Yang B.B.; JiangQ.; HeS.C.; et al. Ventricular SK2 upregulation following angiotensin Ⅱ challenge: modulation by p21-activated kinase-1. J. Mol. Cell. Cardiol., 2022, 164: 110-125.
44.
Binder P.; Wang S.Y.; Radu M.; et al. Pak2 as a novel therapeutic target for cardioprotective endoplasmic reticulum stress response. Circ. Res., 2019, 124(5): 696-711.
45.
Binder P.; Nguyen B.; Collins L.; et al. Pak2 regulation of Nrf2 serves as a novel signaling nexus linking ER stress response and oxidative stress in the heart. Front. Cardiovasc. Med., 2022, 9: 851419.
46.
Ke Y.B.; Wang L.; PyleG.; et al. Intracellular localization and functional effects of P21-activated kinase-1 (Pak1) in cardiac myocytes. Circ. Res., 2004, 94(2): 194-200.
47.
Sheehan K.A.; KeY.B.; WolskaB.M.; et al. Expression of active p21-activated kinase-1 induces Ca2+ flux modification with altered regulatory protein phosphorylation in cardiac myocytes. Am. J. Physiol.: Cell Physiol., 2009, 296(1): C47-C58.
48.
Ryba D.M.; WarrenC.M.; KaramC.N.; et al. Sphingosine-1-phosphate receptor modulator, FTY720, improves diastolic dysfunction and partially reverses atrial remodeling in a Tm-E180G mouse model linked to hypertrophic cardiomyopathy. Circ.: Heart Failure, 2019, 12(11): e005835.
49.
Ke Y.B.; Wang X.; Jin X.Y.; et al. PAK1 is a novel cardiac protective signaling molecule. Front. Med., 2014, 8(4): 399-403.
50.
Wang Y.W.; Tsui H.; BoltonE.L.; et al. Novel insights into mechanisms for Pak1-mediated regulation of cardiac Ca2+ homeostasis. Front. Physiol., 2015, 6: 76.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us